Pluristem and Abu Dhabi Stem Cell Center medical cooperation
The signing of a Memorandum of Understanding between Pluristem and Abu Dhabi Stem Cell Center to collaborate in developing cell therapies and regenerative drugs to treat serious diseases including COVID-19.
The Pluristem and Abu Dhabi Stem Cell Center medical cooperation comes at a time when the United Arab Emirates and Israel reach a historic agreement to fully normalize diplomatic relations
Pluristem and Abu Dhabi Stem Cell Center new biological therapy
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing a platform for new biological therapy products, today on its subsidiary Pluristem Ltd., a non-binding memorandum of understanding (MOU) with the Abu Dhabi Stem Cell Center (ADSCC) based in the UAE United, a specialized healthcare centre focusing on cell therapy and regenerative medicine.
Executives from the two companies Pluristem and Abu Dhabi Stem Cell Center participated in the signing ceremony for a contract via video conference between Israel and the UAE. The aim of this collaboration is to make use of each company’s areas of expertise in cellular therapies to provide regenerative medicine not only for the benefit of the citizens of the United Arab Emirates and Israel but for the benefit of humanity as a whole. The cooperation between the two parties was started by the consulting firm Better Alternatives.
The Pluristem and Abu Dhabi Stem Cell Center agreed to share research results, share samples, join the use of equipment and testing, and other essential activities related to treatment development and research into cell therapies for a wide range of medical conditions, including COVID-19.
The Physiotherapy Clinic Abu Dhabi treats COVID-19 patients with stem cells taken from the patient’s blood, by returning the cells to the patient’s lungs in the form of a fine mist through a nebulizer, which is a machine that helps the patient breathe the medicine through a mask or mouthpiece. Pluristem has treated patients with its placental allogeneic product PLX-PAD via compassionate use programs in Israel and the United States and is currently conducting phase 2 studies in the United States and the European Union.
Pluristem and Abu Dhabi Stem Cell Center statements
“We are extremely proud to partner with our colleagues at the Abu Dhabi Sewerage Services Center by sharing the knowledge and experience that we believe will enhance healthcare within and across our borders. We see life sciences and regenerative medicine as a bridge to building peace, prosperity and well-being in our region and the world at large. I believe it is our duty and privilege as business leaders and scholars to lead the way forward to strengthen cooperation and promote innovation and education. Pluristem CEO and Chairman Yaky Yanay stated, “We are honoured to be at the forefront at this historic moment.”
Dr. Yendry Ventura, General Manager of ADSCC commented, “Pluristem is a major player in the cell therapy field with years of experience, a unique platform and a strong clinical pipeline. We are passionate about joining forces and promoting research and development in cell therapies for the best patients and the human community at large.”
Brief about Pluristem and Abu Dhabi Stem Cell Center
About Abu Dhabi Stem Cell Center
The Abu Dhabi Stem Cell Center (ADSCC) is an Abu Dhabi-based specialized healthcare centre that focuses on cell therapy and regenerative medicine, as well as providing the most recent research on stem cells in the region. The centre was established in March 2019 to meet the growing local and regional demand for highly specialized medical services and treatments.
It Equipped with the latest technology and medical devices unique to the region, and a team of internationally recognized doctors working alongside researchers, Abu Dhabi Medical Services Center is the first of its kind in the United Arab Emirates. The specialities of the Abu Dhabi Center include Immunotherapy, Hematology, Clinical Stem Cell Therapy, Molecular Biology, Immunotherapy, Orthopedics and Urology – among others.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. Is a leading regenerative medicine company developing new products for placenta-based cell therapy. The company has reported robust clinical trial data in multiple indicators of its filter from its patented PLX Cell Products and is currently conducting late-stage clinical trials in several indicators. PLX-cell filter products are thought to release a host of therapeutic proteins in response to inflammation, ischemia, muscle trauma, blood disorders, and radiation damage. Cell culture is done using the company’s own 3D expansion technology and can be given to patients without the need for tissue matching. Pluristem has a strong IP position; Company-owned and GMP-managed manufacturing and research facility; Strategic relationships with major research institutions; And an experienced management team.